NCT02336607已完成不适用
A Randomized, Open-label Study to Evaluate the Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release, Alone and in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide, in Chinese Patients With Mild to Moderate Essential Hypertension.
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 529
- 主要终点
- The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 14 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
研究概览
简要总结
The purpose of this study is to evaluate the effects on blood pressure control, pulse wave velocity, as well as safety and tolerability of felodipine single or combine with other drugs in Chinese Hypertension patients.
详细描述
In this study, investigators will choose male and female subjects aged between 35 and 79 years old with mild to moderate essential hypertension. At first 2 weeks, all patients will use felodipine 5mg daily. If the blood pressure dosen't meet the target (140/90mmHg), they will be randomized into metoprolol, lisinopril or hydrochlorothiazide combination groups for another 4 weeks therapy. After that, if the blood pressure has still not met the target, up-titrate the felodipine into 10mg, followed by a 4 weeks therapy. And if the blood pressure is still not met the target after that, up-titrate the combine drugs into maximum dosage. The whole treatment duration is 14 weeks.
The primary outcome is to evaluate the percentage of subjects reaching blood pressure target (defined as < 140 / 90 mmHg) after 14 weeks treatment with felodipine sustained release in combination with metoprolol, lisinopril or hydrochlorothiazide.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of written informed consent
- •Female or male aged between 35-79 years old
- •Mild to moderate essential hypertension patients who meet any of the following criterias:
- •Newly diagnosed, drug-naive, or without any antihypertension treatment for at least 3 months, moderate essential hypertension patients. (160mmHg mean SiSBP 180mmHg or 100mmHg mean SiDBP 110mmHg)
- •Newly diagnosed, drug-naive, or without any antihypertension treatment for at least 3 months, mild essential hypertension patients (140mmHg mean SiSBP 160mmHg or 90mmHg mean SiDBP 100mmHg) with high or extreme high cardiovascular risk (a)(having 3 or more than 3 risk factors and/or target organ lesion and/or diabetes mellitus).
- •(a) according to Chinese guideline for prevention and treatment of patients with hypertension
- •The patients have already received starting dosage of single anti-hypertension drug therapy (exclude the drugs containing felodipine component ), however the blood pressure is not well controlled (140mmHg mean SiSBP 160mmHg or 90mmHg mean SiDBP 100mmHg). After stopping the drug for 5 eliminating half life time, the patients meet any one of the following two:
- •160mmHg mean SiSBP 180mmHg or 100mmHg mean SiDBP 110mmHg.
- •140mmHg mean SiSBP 160mmHg or 90mmHg mean SiDBP 100mmHg) with high or extreme high cardiovascular risk* (having 3 or more than 3 risk factors and/or target organ lesion and/or diabetes mellitus).
- •Sitting blood pressure is taken after subjects take a seat to rest for 5 minutes before the next medication.
排除标准
- •Any of the following is regarded as a criterion for exclusion from the study:
- •Known or suspected secondary hypertension
- •Resting heart rate is < 55bpm.
- •Sick sinus syndrome
- •Atrioventricular block of first degree (with P-R>0.24seconds), or second or third degree
- •Other clinical significant arrhythmia
- •Unstable and/or decompensated congestive heart failure
- •Angina, acute myocardial infarction, percutaneous coronary intervention (PCI), or cardiac surgery
- •Asthma or moderate to severe chronic obstructive pulmonary disease
- •Type 1 diabetes mellitus
- •Gout history
- •Fasting serum glucose of greater than 200 mg/dl (11.1 mmol/L) or type 2 diabetes mellitus needs insulin therapy
- •Cr>1.5mg/dl
- •Pregnancy or lactation.
- •Alcohol or drug abuse
- •Known need for other concomitant anti-hypertensive therapy during the study besides the study drug.
- •Known or suspected allergy to investigational drug or non-active ingredients of investigational drugs, known allergy to other blockers, calcium antagonist, diuretics, angiotensin converting enzyme inhibitor or with other contraindications.
- •Suspected white-coat hypertension based on investigator's judgement.
研究组 & 干预措施
Felodipine tablet (Plendil)
Experimental
干预措施: Felodipine tablet (Plendil) alone (Drug)
Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)
Active Comparator
干预措施: Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK) (Drug)
Felodipine tablets (Plendil)+Lisinopril (Zestril)
Active Comparator
干预措施: Felodipine tablets (Plendil)+Lisinopril (Zestril) (Drug)
Felodipine tablet (Plendil)+Hydrochlorothiazide
Active Comparator
干预措施: Felodipine tablet (Plendil)+Hydrochlorothiazide (Drug)
结局指标
主要结局
The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 14 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
时间窗: 14 weeks
次要结局
- The Change of Pulse Wave Velocity From Baseline at 2, 14 Weeks of Felodipine Sustained Release Alone.(12 weeks)
- The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 2 Weeks of Felodipine Sustained Release, Alone(2 weeks)
- The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.(8 weeks)
- The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.(4 weeks)
- The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.(4 weeks)
- The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.(8 weeks)
- The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 12 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.(12 weeks)
- The Change of Pulse Wave Velocity at 12 Weeks Compare With Baseline Data of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.(12 weeks)
- The Magnitude of Systolic and Diastolic Blood Pressure Change From Baseline Among All Randomized Subjects After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.(4 weeks)
- The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among All Randomized Subjects After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.(8 weeks)
- The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among All Randomized Subjects After 12 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.(12 weeks)
研究者
相似试验
已完成
3 期
Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With HypertensionHypertensionNCT00142584Mylan Bertek Pharmaceuticals336
已完成
1 期
Drug Interaction Study of Avanafil and Enalapril or AmlodipineErectile DysfunctionNCT01117038VIVUS LLC48
已完成
不适用
China Antihypertensive Trial for Intracranial AneurysmUnruptured Intracranial AneurysmHypertensionNCT05941377Beijing Tiantan Hospital577
已完成
3 期
Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.Essential HypertensionNCT00343551Novartis654
已完成
不适用
Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern in Kidney Transplant RecipientsBlood Pressure ControlKidney Transplant RecipientNCT01093703Mayo Clinic99